Nora Medina Meleán’s Post

Semaglutide treatment for 24 weeks resulted in a clinically meaningful reduction in albuminuria in patients with overweight/obesity and non-diabetic CKD. There was also reduction in BP, hsCRP and NT-proBNP. https://lnkd.in/eAnCuAcj

Romosozumab vs. Teriparatide in Postmenopausal Osteoporosis The effectiveness/safety of ROMO and TPTD were compared in a clinical setting, and ROMO showed greater increases in BMD than TPTD after 12 months of therapy, along with a higher completion rate. https://buff.ly/4dpzPMB

In this clip from our recent pearl, discover how intensive atorvastatin therapy improves endothelial function and reduces inflammation in STEMI patients undergoing primary PCI. Dive into the 2016 study by Xu X, Liu Y, Li K, et al. Visit our website to learn more. #PharmacyPearls #EmergencyMedicine #Statins #STEMI #Atorvastatin #PrimaryPCI

Romosozumab vs. Teriparatide in Postmenopausal Osteoporosis The effectiveness/safety of ROMO and TPTD were compared in a clinical setting, and ROMO showed greater increases in BMD than TPTD after 12 months of therapy, along with a higher completion rate. https://buff.ly/4djC7Nq

🔬 Understand therapeutic monitoring for ALL/LBL patients on asparaginase therapies. Recognize associated toxicities and select the best treatment approach. Manage treatment and communicate effectively with patients and families 💬 http://ms.spr.ly/6043Y9EMc

Exciting news! Researchers have made a major breakthrough in understanding IBD, which could lead to new treatments using existing drugs. Dr. James Lee from The Francis Crick Institute shared that their findings reveal "one of the very central pathways that goes wrong when people get inflammatory bowel disease." This discovery is a crucial step towards understanding and treating IBD more effectively. Ruth Wakeman at Crohn's & Colitis UK highlights this as a "step towards the possibility of a world free from Crohn’s and colitis." Our mission at Crohn's Colitis Cure is to improve care now and be instrumental in finding a cure for IBD. Join us in celebrating this important milestone! Read more: https://lnkd.in/g7yAd2pm #IBDBreakthrough #CrohnsDisease #UlcerativeColitis #MedicalResearch #CrohnsColitisCure #IBDAwareness #HealthcareAdvancements #ResearchForACure #FutureOfHealth

#OBRxBrands #OurWorkWednesday COSENTYX is indicated for the treatment of: – moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy. – active psoriatic arthritis (PsA) in patients 2 years of age and older. – adult patients with active ankylosing spondylitis (AS). – adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. – active enthesitis-related arthritis (ERA) in patients 4 years of age and older. – adult patients with moderate to severe hidradenitis suppurativa (HS). To Learn More: https://lnkd.in/esDs8SVY #OptiBrand #OptiBrandRx #OBRx #OWW #Pharma #PharmaMarketResearch #PharmaStrategy #strategy #marketresearch #getmore #PharmaExperts 

🔬 Understand therapeutic monitoring for ALL/LBL patients on asparaginase therapies. Recognize associated toxicities and select the best treatment approach. Manage treatment and communicate effectively with patients and families 💬 http://ms.spr.ly/6041YX171

Join the conversation on innovative treatments and personalized approaches for managing #RheumatoidArthritis. Discover how #PrecisionMedicine and advanced therapies are improving outcomes for patients with #DifficultToTreat RA. https://lnkd.in/d78iQxXq

#ICYMI: Alzheimer disease and related dementias (#ADRD) are associated with significantly higher total and out-of-pocket #prescription drug #costs, according to study findings. Learn more: https://bit.ly/4fGGmE5 #AlzheimersDiseaseAwarenessMonth